Loading...

Course Description

Bundled Courses: 
IMMU 418 I Cancer Immunology
IMMU 419 I Cancer Immunotherapy

This bundle integrates foundational knowledge of tumor–immune system interactions with applied approaches to developing and evaluating cancer immunotherapies. IMMU 418 (Cancer Immunology) introduces how immune cells, inflammatory processes, and the tumor microenvironment interact to either suppress or promote cancer progression. Students will examine mechanisms of immune evasion, macrophage polarization, myeloid-derived suppressor cell function, viral contributions to cancer, and antibody-based targeting strategies, establishing a strong conceptual framework for understanding cancer–immune system dynamics.

Building on this foundation, IMMU 419 (Cancer Immunotherapy) focuses on how these biological principles are harnessed to train or redirect the immune system to recognize and eliminate cancer cells. Students will trace the development of immunotherapies from early cytokine-based interventions to modern checkpoint inhibitors, cancer vaccines, adoptive cell transfer, CAR-T therapies, antibody therapeutics, and oncolytic viruses. The course also examines current clinical trial approaches and emerging research directions. Together, these courses equip learners to critically evaluate immunotherapeutic strategies and understand where innovation is needed to address remaining challenges in cancer treatment.

Learner Outcomes

When you complete these courses successfully, you will be able to: 

  • Explain how the immune system recognizes and responds to cancer cells, including how tumors alter and evade these responses.
  • Describe key features of the tumor microenvironment and how immune cell infiltration, regulation, and suppression influence cancer progression.
  • Evaluate mechanisms of immune escape and identify points at which therapeutic intervention can restore or enhance anti-tumor immunity.
  • Compare major classes of cancer immunotherapies, including vaccines, cytokine-based therapies, checkpoint inhibitors, monoclonal antibodies, and adoptive cell therapies.
  • Assess the benefits, limitations, and clinical considerations of current immunotherapeutic strategies in both research and treatment contexts.
  • Discuss emerging and experimental approaches in cancer immunotherapy and identify ongoing challenges and opportunities for future innovation.

Microcredential(s):

These courses apply towards the Biomedical Sciences Endeavor and the Advanced Cancer Biology digital badges. 

     

Textbook Information

There is no textbook for purchase required for these courses.

Prerequisites

IMMU 418: There are no prerequisites required for this course
IMMU 419: Familiarity with basic immunology is required. Prior college-level coursework in immunology is highly encouraged. 

Refund

Follow the link to review FAES Tuition Refund Policy.

If you cancel a course, the bundled price no longer applies and you need to pay the individual course and technology fees. 

Scholarship and Funding

Are you a self-funded student? FAES offers scholarship options. Click here for more information and to apply. 

Looking for resources to help you acquire funding for your continued education? Click here for our funding justification guide. 

Photo Release

By registering for this event, you agree to allow FAES to take photographs of you during the event and to use these photos for promotional purposes, including on our website, social media, and marketing materials, without further compensation. You understand that you have no right to review or approve the final use of these images.

Loading...

To Register Click on "Add to Cart"

Section Title
2-COURSE BUNDLE - Cancer Immunology and Immunotherapy
Type
Online Asynchronous
Dates
Jan 28, 2026 to May 12, 2026
Total Cost (Includes $75 non-refundable technology fee per course when applicable)
Eligible Discounts Can Be Applied at Checkout (2 Credits) $640.00
Potential Discount(s)
Available for Academic Credit
2 Credit(s)
Required fields are indicated by .